

NOVADEL PHARMA INC
Form 8-K
June 08, 2005

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) June 2, 2005

NOVADEL PHARMA INC.
(Exact Name of Registrant as Specified in Its Charter)

**Delaware
(State or other
jurisdiction
of incorporation)**

001-32177
(Commission File No.)

22-2407152
**(I.R.S. Employer
Identification No.)**

25 Minneakoning Road
Flemington, New Jersey 08822
(Address of principal executive offices) (Zip Code)

(908) 782-3431
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events

On June 2, 2005, NovaDel Pharma Inc. (the “Company”) issued a press release to announce that the Company received an approvable letter from the U.S. Food and Drug Administration regarding its New Drug Application (NDA) for NitroMist™(nitroglycerin lingual aerosol), indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. The full text of the press release is set forth in Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1. Press release dated June 2, 2005, titled “NovaDel Pharma Receives Approvable Letter from the FDA for NitroMist™(nitroglycerin lingual aerosol).”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma Inc.

By: /s/ Jean W. Frydman

Name: Jean W. Frydman
Title: Vice President and General Counsel

Date: June 8, 2005

EXHIBIT INDEX

Exhibit Description

99.1 Press release dated June 2, 2005, titled “NovaDel Pharma Receives Approvable Letter from the FDA for NitroMist™(nitroglycerin lingual aerosol).”
